None
Conditions
Interventions
fospropofol group (Group FP):During anesthesia induction, sufficient pre-oxygenation was given. Then, 2-3 mg of midazolam and 0.3 µg/kg of sufentanil were slowly injected. Sedatives were injected 1 to
Sponsors
The Second Norman Bethune Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.If any of the following items is "No", this patient cannot participate in the trial (1)Age: 18-65 years old, gender not limited; (2) American Society of Anesthesiologists (ASA) : Grade ?-?; (3) Body Mass Index (BMI) : 18.5-30 kg/m ²; (4) Elective surgery needs to be performed under general anesthesia, and the estimated operation time is more than 30 minutes. (5) Voluntarily participated and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Those who present any of the following will be excluded from this study (1) Those with contraindications to general anesthesia or those who have a history of anesthesia accidents in the past; (2) Those with combined craniocerebral loss, intracranial hypertension and stroke; (3) Combined with known cardiovascular diseases, such as essential hypertension, unstable angina pectoris, heart failure, valvular heart disease, etc. Respiratory insufficiency, obstructive pulmonary disease, presence of difficult airways or determination of difficult tracheal intubation (modified Markov scale grade III or IV) (4) Uncontrolled diabetes or hypertension; (5) History of drug abuse, alcohol abuse or drug dependence; (6) Abuse or long-term use of anesthetic, sedative and analgesic drugs; (7) Those who are known or suspected of being allergic or contraindicated to the various components of the investigational drug or the prescribed process-based medication in the protocol (sufentanil citrate injection, medium/long chain fat emulsion of propofol, remifentanil hydrochloride for injection, disodium propofol phosphate for injection); (8) Those with a history of mental illness; (9) Those who have participated in any drug clinical trials within one month prior to the screening; (10) Pregnant and lactating women; Fertile women or men are unwilling to use contraception throughout the trial period; Subjects (including male subjects) who have pregnancy plans within one month after the trial; (11) Subjects who the researchers consider to have any other factors that make them unsuitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LVEF;E/A;Cardiac output; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-invasive arterial blood pressure;Heart rate; | — |
Countries
China
Contacts
Public ContactTian Dan
The Second Hospital of Jilin University
Outcome results
None listed